socalTECH

JULY 17, 2014

The latest venture capital totals from the PricewaterhouseCoopers/National Venture Capital Association''s MoneyTree Report was released this evening, tallying up $761.12M in investments in Q2 of 2014 in Southern California, up from Q2 of 2013, when $616.83M was invested in the region. Nationally, there was $13.0

Southern California 240

Southern California El Segundo Culver City Orange County 240

socalTECH

SEPTEMBER 10, 2014

San Diego-based Avelas Biosciences , which is developing cell penetrating peptides to light up cancerous tissue in patients during surgery, has raised $7.4M The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments. in a Series B funding.

Avalon 147

Avalon San Diego Venture Capital Research 147

socalTECH

JANUARY 9, 2014

The company said the funding came from Avalon Ventures, and also included Torrey Pines Investment, WuXi AppTec, and an additional, un-named investor. Avelas Biosciences is developing a flourecent peptide which helps surgeons highlight cancer cells during surgery, specifically for breast cancer. READ MORE>>.

Avalon 138

Avalon San Diego Funding Capital 138

socalTECH

AUGUST 18, 2016

San Diego-based biopharmaceuticals developer Avelas Biosciences has raised $20M in a Series C funding, according to the company. and laos included Ervington Investments Limited and Alexandria Venture Investments plus Avalon Ventures, Bregua Corporation, and WuXi Healthcare Ventures.

Avalon 100

Avalon San Diego Invest Funding 100

socalTECH

JUNE 4, 2012

San Diego-based Awarepoint , which develops real-time, location systems used for tracking patents and assets in a healthcare environment, said today that it has raised $14M in an additional financing round. of the new investment round, which the company said will go to expand its services, client management, and manufacturing capabilities.

Avalon 140

Avalon San Diego Patents Invest 140

Xconomy

AUGUST 17, 2016

Pharmstandard International, the Luxembourg-based investment arm of the Russian pharmaceutical giant Pharmstandard (and a first-time investor in Avelas), led the round. It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp.,

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

JULY 19, 2016

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

JANUARY 26, 2017

biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. Stockholders who had invested in the. AnaptysBio is the first U.S. Anaptys also sold 1 million more shares that it had initially planned.

Marketing 40

Marketing San Diego Invest Help 40